Wegovy (semaglutide) is a prescription-only GLP-1 weight-loss injection that has been clinically proven to support significant and sustained weight loss when combined with dietary and lifestyle changes. It works by mimicking the hormone GLP-1 (glucagon-like peptide-1), which plays a key role in appetite regulation, digestion, and blood-sugar control.

This guide explains how weight loss with Wegovy typically progresses over time, what results patients may expect at different stages, and which factors influence individual outcomes.

How Does Wegovy Support Weight Loss?

Wegovy works by activating GLP-1 receptors in the brain and digestive system. These effects help to:

  • Reduce appetite and food cravings

  • Increase feelings of fullness after meals

  • Slow gastric emptying

  • Improve blood-sugar control

Together, these mechanisms reduce overall calorie intake and support gradual, sustainable weight loss when used alongside a calorie-controlled diet and increased physical activity [1][2]. 

How Wegovy Compares to Other Weight-Loss Injections

Wegovy (semaglutide) is a GLP-1 receptor agonist that supports weight loss by reducing appetite and slowing digestion. Other prescription weight-loss injections may act on additional hormone pathways and can lead to different average outcomes for some patients.

Clinical trials suggest that Mounjaro (tirzepatide), which activates both GLP-1 and GIP receptors, may lead to greater average weight loss than Wegovy for some patients, although individual results vary and suitability depends on medical history and tolerance. 

How Long Does Wegovy Take to Work?

Most patients begin to notice the effects of Wegovy within the first 1 to 4 weeks of treatment, although these early changes are usually related to appetite rather than significant weight loss.

During this initial phase, Wegovy works by reducing hunger, increasing fullness, and helping control portion sizes. Many patients report eating less and feeling satisfied more quickly, even before seeing measurable changes on the scale.

More noticeable weight loss typically begins after 4 to 8 weeks, as the dose is gradually increased and appetite suppression becomes more consistent. By this stage, patients often find it easier to maintain a calorie deficit, which is key to achieving sustained results. If you want to estimate how this may translate into expected progress, you can use our Wegovy weight loss calculator to model potential outcomes based on your calorie intake and target weight.

By around 8 to 12 weeks, weight loss is usually steady and ongoing, particularly when combined with a structured diet and regular physical activity.

Wegovy is designed to produce gradual, clinically meaningful weight loss over time, rather than rapid short-term results. Clinical studies show that the most significant outcomes occur over several months as patients reach and maintain the full therapeutic dose [3][4].

Wegovy Weight-Loss Timeline: What to Expect

Wegovy follows a structured dose-escalation timeline, which means results develop progressively over time rather than immediately. While many patients begin to notice appetite changes within the first few weeks, the timeline below explains how weight loss typically develops at each stage of treatment.

Weeks 1–4: Starting Treatment

During the first month, Wegovy is introduced at a low dose to allow the body to adjust. At this stage, the primary effect is appetite suppression rather than significant weight loss.

Patients commonly experience:

  • Reduced hunger

  • Feeling full more quickly

  • Early changes in eating habits

Weight loss may begin during this phase, but for many patients, measurable results become more noticeable in later stages as the dose increases.

Weeks 5–8: Appetite Suppression & Early Weight Loss

As the dose is increased, appetite suppression becomes more consistent for many patients.

Typical experiences during this stage include:

  • Reduced hunger between meals

  • Improved portion control

  • Gradual weekly weight loss

Clinical trial data shows that weight reduction often becomes more noticeable after the first month of treatment [3].

Weeks 9–12: Steady Progress

By this stage, many patients have reached a higher maintenance dose.

Common outcomes include:

  • Ongoing, steady weight loss

  • Improved blood-sugar control

  • Better energy levels as weight decreases

Studies demonstrate continued weight loss during this phase when Wegovy is combined with lifestyle changes [3][4].

3–6 Months: Clinically Meaningful Weight Loss

After several months of treatment, many patients achieve clinically meaningful weight loss, defined as a reduction that improves metabolic and cardiovascular health.

Reported benefits include:

  • Significant percentage reduction in body weight

  • Improvements in cholesterol and blood-sugar markers

  • Reduced obesity-related health risks

Longer treatment duration is associated with greater average weight loss [4].

12 Months and Beyond: Long-Term Results

Clinical trials show that patients who continue Wegovy long term may maintain or further improve their weight-loss results over time.

Discontinuing treatment can lead to weight regain, which is why ongoing medical supervision and lifestyle support are important [4].

Average Weight-Loss Results with Wegovy

In large clinical trials, patients using semaglutide 2.4 mg achieved significantly greater average weight loss than placebo.

Studies have reported:

  • Average weight loss of around 15% of body weight over 68 weeks

  • Greater weight reduction with continued treatment

  • Sustained results when lifestyle changes are maintained

These results represent clinical trial averages and may not reflect individual outcomes [3][4].

Factors That Influence Wegovy Results

Individual weight-loss outcomes can vary depending on:

  • Starting BMI

  • Dose and treatment duration

  • Diet and calorie intake

  • Physical activity levels

  • Adherence to treatment

  • Underlying metabolic conditions

Diet plays a major role in both weight-loss results and side-effect management. Our guide on what to eat while using weight loss injections explains how food choices can support appetite control, improve tolerance, and help maintain steady progress while using GLP-1 treatments.

Wegovy works best as part of a long-term weight-management plan, not as a standalone solution [2].

Important Safety Information

Wegovy is a prescription-only medicine and is not suitable for everyone. It must be prescribed following a medical assessment and used alongside dietary and lifestyle changes.

Common side effects include nausea, vomiting, diarrhoea, and constipation, particularly during dose increases. For a full breakdown of expected side effects, how long they typically last, and when to seek medical advice, see our weight-loss injection side effects explained guide.

Start Your GLP-1 Treatment Safely

Complete our quick and secure online consultation. Our pharmacy team will review your answers and advise on the most suitable GLP-1 weight-loss treatment for you.

Start Your Weight Loss Consultation

FAQs

How long does Wegovy take to start working?
Wegovy typically starts working within the first few weeks by reducing appetite, with noticeable weight loss usually occurring after 4 to 8 weeks. See the full timeline above for a detailed breakdown.
How much weight can you lose on Wegovy?
Clinical trials show that patients using Wegovy (semaglutide 2.4 mg) lost an average of around 15% of their body weight over 68 weeks. Some people lose more, while others lose less depending on factors such as starting weight and adherence.
What does the Wegovy weight-loss timeline look like?
Weight loss with Wegovy is gradual. Early appetite reduction often occurs within weeks, with more noticeable weight loss typically seen after 1–2 months. Clinically meaningful weight loss is commonly achieved after 3–6 months of consistent treatment.
Why is Wegovy started at a low dose?
Wegovy doses are increased gradually to help reduce the risk of side effects, particularly nausea and gastrointestinal symptoms. This allows the body time to adjust before reaching the full maintenance dose.
Is weight loss faster on Wegovy or Mounjaro?
Clinical trials suggest that Mounjaro (tirzepatide) may lead to greater average weight loss than Wegovy. However, individual results vary, and suitability depends on medical history, tolerance, and prescriber assessment.
Can you regain weight after stopping Wegovy?
Yes. Studies show that stopping Wegovy can lead to weight regain, especially if lifestyle changes are not maintained. Wegovy is intended as part of a long-term weight-management plan.
Do you need to diet while taking Wegovy?
Yes. Wegovy works best when combined with a calorie-controlled diet and increased physical activity. The medication helps reduce appetite, making dietary changes easier to maintain.
What are the most common side effects of Wegovy?
Common side effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during dose increases. These effects are usually mild to moderate and often improve over time.
Is Wegovy suitable for everyone?
No. Wegovy is not suitable for people who are pregnant or breastfeeding, those with certain medical conditions, or individuals taking other GLP-1 medicines. A medical assessment is required before starting treatment.
How long do you need to stay on Wegovy to maintain results?
Many people need to continue Wegovy long term to maintain weight loss. Ongoing treatment, combined with lifestyle changes, helps support sustained results and reduce the risk of weight regain.

References

1. Wegovy (Semaglutide) – How It Works (GLP-1 Mechanism)

• Wegovy: how it works (GLP-1 appetite + slower digestion) – Diabetes UK

2. Clinical Guidance & Use Alongside Lifestyle Changes

• Semaglutide for managing overweight and obesity (technology appraisal) – NICE TA875
• Obesity treatment and management (diet, activity and treatment options) – NHS

3. Wegovy Weight-Loss Results (STEP-1 Trial – 68 Weeks)

• Once-weekly semaglutide in adults with overweight or obesity (STEP-1 primary publication) – New England Journal of Medicine

4. STEP-1 Supporting Record (Abstract/Index + Trial Registration)

• STEP-1 (Once-weekly semaglutide in adults with overweight or obesity) – PubMed
• STEP-1 Trial Registration (NCT03548935) – ClinicalTrials.gov

Medically Reviewed by Our GPhC-Registered Pharmacists

GPhC Logo National Pharmacy Association Logo
Palvinder Deol

Authored by:

Palvinder Deol
Superintendent Pharmacist
Over 25 years’ clinical experience.
Nigel Howard

Reviewed by:

Nigel Howard
Independent Prescriber
Over 20 years’ clinical experience.

GPhC Inspection Result

General Pharmaceutical Council Logo

Inspection Outcome: All Standards Met

Our digital-first pharmacy achieved rare “Good Practice” recognition during our GPhC inspection on 19 May 2025 — showcasing our commitment to safe, high-quality and innovative online healthcare.

View full inspection report →

GPhC Registration No. 9012585 | Inspected 19 May 2025